Поражение печени при псориазе и псориатическом артрите: обзор литературы
https://doi.org/10.14412/1995-4484-2017-429-435
Аннотация
Псориаз (Пс) является хроническим системным заболеванием, поражающим кожу. Исследования позволили выявить высокую распространенность неалкогольной жировой болезни печени (НАЖБП) у больных Пс по сравнению с общей популяцией, особенно у тех, кто страдает среднетяжелыми и тяжелыми формами Пс с высоким индексом распространенности и тяжести Пс (PASI). Определенную роль в этой взаимосвязи играют аналогичные патогенетические процессы. Среди наиболее вероятных причин выделяют резистентность к инсулину и повышение уровней провоспалительных цитокинов. По последним данным, распространенность НАЖБП и метаболического синдрома среди больных Пс выше, чем в популяции в целом. Кроме того, пациенты с НАЖБП и Пс имеют более высокий риск развития тяжелого фиброза печени, чем лица с НАЖБП и без Пс. Терапия этого состояния несомненно должна проводиться по пути не только модификации традиционных факторов риска, но и надежного подавления воспаления. Наличие ожирения и НАЖБП оказывает отрицательное влияние и на результаты лечения больных псориатическим артритом генно-инженерными биологическими препаратами.
Об авторах
Ю. Л. Корсакова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
115522 Москва, Каширское шоссе, 34А
Т. В. Коротаева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522 Москва, Каширское шоссе, 34А
Россия
115522 Москва, Каширское шоссе, 34А
Список литературы
1. Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785-96. doi: 10.1038/jid.2010.103
2. Christophers E. Psoriasis – epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314-20. doi: 10.1046/j.1365-2230.2001.00832.x
3. Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899-912. doi: 10.1056/NEJMra041320
4. Ganzetti G, Campanati A, Scocco V, et al. The potential effect of the tumour necrosis factor-α inhibitors on vitamin D status in psoriatic patients. Acta Derm Venereol. 2014;94:715-7. doi: 10.2340/00015555-1801
5. Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25:510-8. doi: 10.1016/j.clindermatol. 2007.08.003
6. Koo J, Lee E, Lee CS, et al. Psoriasis. J Am Acad Dermatol. 2004;50:4. doi: 10.1016/j.jaad.2003.11.046
7. Rivera R, Vanaclocha F. Nonalcoholic fatty liver disease and psoriasis. Actas Dermosifiliogr. 2010;101:657-8. doi: 10.1016/j.ad.2010.06.004
8. Farley E, Menter A. Psoriasis: comorbidities and associations. Ital Dermatol Venereol. 2011;146:9-15.
9. Ramos AN, de Oliveira Rocha B, de Almeida Rego V, et al. The linkage between psoriasis and non-alcoholic fatty liver disease: a literature review. Acta Dermatovenerol Croat. 2014;22(2):132-6.
10. Boehncke WH, Boehncke S. More than skin-deep: the many dimensions of the psoriatic disease. Swiss Med Wkly. 2014;144:w13968. doi: 10.4414/smw.2014.13968
11. Gisondi P, Targher G, Zoppini G, et al. Non-alcoholic fatty liver disease in patients with chronic plaques psoriasis. J Hepatol. 2009;51:758-64. doi: 10.1016/j.jhep.2009.04.020
12. Torres T, Bettencourt N. Psoriasis: the visible killer. Rev Port Cardiol. 2014;33:95-9. doi: 10.1016/j.repc.2013.06.017
13. Onumah N, Kircik LH. Psoriasis and its comorbidities. J Drugs Dermatol. 2012;11:s5-10.
14. Paschos P, Paleta K. Nonalcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13:9-19.
15. Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat. 2010;18:297-304.
16. Ludwig J, Viqgiano TR, McGill DB, et al. Nonalcoholic statohepatitis: Meyo Clinic experience with a hitherto unnamed disease. Meyo Clin Proc. 1980;55:434-8.
17. Farrel GC, Larter CZ. Non-alcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology. 2006;43:S99-S112. doi: 10.1002/hep.20973
18. Полунина ТЕ, Маев ИВ. Неалкогольная жировая болезнь печени: эпидемиология, патогенез, диагностика, лечение. Consilium medicum. Гастроэнтерология. 2012;(1):35-40 [Polunina TE, Maev IV. Non-alcoholic fatty liver disease: epidemiology, pathogenesis, diagnosis, treatment. Consilium Medicum. Gastroenterologiya. 2012;(1):35-40 (In Russ.)].
19. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-84. doi: 10.1016/j.jhep.2010.04.008
20. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). EASLEASD- EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-402. doi: 10.1016/j.jhep.2015.11.004
21. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med. 2005;22:1129-33. doi: 10.1111/j.1464-5491.2005.01748.x
22. Bitencourt AGV, Cotrim HP, Alves E, et al. Doenca hepatica gordurosa nao alcoolica: caracteristicas clinicas e histologicas em obesos graves submetidos a cirurgia bariatrica. Acta Gastroenterol Latinoam. 2007;37:224-30.
23. Kotronen A, Yki-Jä rvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:27-38. doi: 10.1161/ATVBAHA.107.147538
24. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-95. doi: 10.1002/hep.20466
25. Karnikowiski M, Cordova C, Oliveira RJ, et al. Non-alcoholic fatty liver disease and metabolic syndrome in Brazilian medianaged and older adults. Sao Paulo Med J. 2007;125:333-7. doi: 10.1590/S1516-31802007000600006
26. Anstee QM, Daly AK, Day CP. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis. 2011;31:128-46. doi: 10.1055/s-0031-1276643
27. Leonardo A, Loria P, Carulli N. Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLI. ST.E.N.A. study. Dig Liver Dis. 2001;33:86-7 [PMID: 11303985].
28. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-54. doi: 10.1002/hep.21496
29. Vanni E, Bugianesi E, Kotronen A, et al. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42:320-30. doi: 10.1016/j.dld.2010.01.016
30. Mantovani A, Gisondi P, Lonardo A, et al. Relationship between non-alcoholic fatty liver disease and psoriasis: A novel hepatodermal axis? Int J Mol Sci. 2016;17:217. doi: 10.3390/ijms17020217
31. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non- alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:778-86. doi: 10.1016/j.jhep.2009.06.008
32. Madanagobalane S, Anandan S. The increased prevalence of nonalcoholic fatty liver disease in psoriaticpatients: A study from South India. Australas J Dermatol. 2012;53:190-7. doi: 10.1111/j.1440-0960.2012.00905.x
33. Van der Voort EA, Koehler EM, Dowlatshahi EA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol. 2014;70:517-24. doi: 10.1016/j.jaad.2013.10.044
34. Van der Voort EA, Koehler EM, Nijsten T, et al. Increased prevalence of advanced liver fibrosis in patients with psoriasis: A crosssectional analysis from the Rotterdam study. Acta Derm Venereol. 2016;96:213-7. doi: 10.2340/00015555-2161
35. Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol. 2015;30:282-7. doi: 10.1111/jdv.13456
36. Abedini R, Salehi M, Lajevardi V, et al. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol. 2015;40:722-7. doi: 10.1111/ced.12672
37. Roberts KK, Cochet AE, Lamb PB, et al. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther. 2015;41:293-300. doi: 10.1111/apt.13042
38. Candia R, Ruiz A, Torres-Robles R, et al. Risk of non-alcoholic fatty liver disease in patients with psoriasis: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29:656-62. doi: 10.1111/jdv.12847
39. Das UN. Is obesity an inflammatory condition? Nutrition. 2001;17:953-66. doi: 10.1016/S0899-9007(01)00672-4
40. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-56. doi: 10.1210/jc.2004-0395
41. Campanati A, Ganzetti G, Marra M, et al. Serum levels of adipocytokines in psoriatic patients receiving TNF-alpha inhibitors: results of a retrospective analysis. Intern J Dermatol. 2015;54:839-45. doi: 10.1111/ijd.12706
42. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxford). 2006;64:355-65. doi: 10.1111/j.1365-2265.2006.02474.x
43. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380:24-30. doi: 10.1016/j.cca.2007.01.026
44. Xu A, Wang Y, Keshaw H, et al. The fatderived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91-100. doi: 10.1172/JCI200317797
45. Masaki T, Chiba S, Tatsukawa H, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology. 2004;40:177-84. doi: 10.1002/hep.20282
46. Polyzos SA, Toulis KA, Goulis DG, et al. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and metaanalysis. Metabolism. 2011;60:313-26. doi: 10.1016/j.metabol.2010.09.003
47. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784-92. doi: 10.1172/JCI29126
48. Targher G, Bertolini L, Scala L, et al. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxford). 2004;61:700-3. doi: 10.1111/j.1365-2265.2004.02151.x
49. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheum. 2016 May;68(5):1060-71. doi: 10.1002/art.39573
50. Vilarrasa E, Puig L, Alomar A. Biologic treatments for psoriasis in patients with hepatitis C virus infection and other liver diseases: experience in 29 patients. JEADV. 2010;24:P013.
51. Schramm C, Schneider A, Marx A, et al. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol. 2008;46:1369-71. doi: 10.1055/s-2008-1027411
52. Bhutani T, Hong J, Koo J. Contemporary diagnosis and management of psoriasis. 5th ed. Newtown, PA: Handbooks in Healthcare; 2011. P. 50-9.
53. Toussirot E, Aubin F, Dumoulin G. Relationships between adipose tissue and psoriasis, with or without arthritis. Front Immunol. 2014;5:368. doi: 10.3389/fimmu.2014.00368
54. Di Minno MND, Peluso R, Iervolino S, et al. Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study. Arthritis Res Ther. 2012;14(5):R211. doi: 10.1186/ar4049
55. Di Minno MND, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2014;73:1157-62. doi: 10.1136/annrheumdis-2012-202812
56. Di Minno MND, Peluso R, Iervolino S, et al. Obesity and the prediction of minimal disease. Arthritis Care Res. 2013;65(1):141-7. doi: 10.1002/acr.21711
57. Hojgaard P, Glintborg B, Kristensen LE, et al. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford). 2016 Dec;55(12):2191-9. doi: 10.1093/rheumatology/kew326
Рецензия
Для цитирования:
Корсакова Ю.Л., Коротаева Т.В. Поражение печени при псориазе и псориатическом артрите: обзор литературы. Научно-практическая ревматология. 2017;55(4):429-435. https://doi.org/10.14412/1995-4484-2017-429-435
For citation:
Korsakova Yu.L., Korotaeva T.V. LIVER DAMAGE IN PSORIASIS AND PSORIATIC ARTHRITIS: A LITERATURE REVIEW. Rheumatology Science and Practice. 2017;55(4):429-435. (In Russ.) https://doi.org/10.14412/1995-4484-2017-429-435
Просмотров:
13855
Послать статью по эл. почте 